ALPMY - Seagen/ Astellas succeed in Phase 3 trial for bladder cancer therapy
2023-10-23 14:25:26 ET
More on Seattle Genetics
- Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors
- Seagen ticks higher as EU approves $43B sale to Pfizer
- Pfizer likely turned over all documents to FTC for Seagen acquistion - report
- Seeking Alpha’s Quant Rating on Seattle Genetics
- Historical earnings data for Seattle Genetics
For further details see:
Seagen/ Astellas succeed in Phase 3 trial for bladder cancer therapy